ISSN: 1359-4117

Journal Home

Journal Guideline

Journal of Experimental Therapeutics and Oncology Q4 Unclaimed

Old City Publishing United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Experimental Therapeutics and Oncology is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 40. It has an SJR impact factor of 0,108 and it has a best quartile of Q4. It is published in English. It has an SJR impact factor of 0,108.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q4) Drug Discovery (Q4) Pharmacology (Q4)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Journal of Experimental Therapeutics and Oncology

0,108

SJR Impact factor

40

H Index

0

Total Docs (Last Year)

5

Total Docs (3 years)

0

Total Refs

0

Total Cites (3 years)

4

Citable Docs (3 years)

0

Cites/Doc (2 years)

0.0

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Journal of HerbMed Pharmacology Q4
Natural Product Sciences Q4
Pharmaceutical Chemistry Journal Q4
Current Enzyme Inhibition Q4
Medicinal Plants - International Journal of Phytomedicines and Related Industries Q4

Compare this journals

Aims and Scope

Best articles by citations

Interleukin-1alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells

Inhibitory effect of vitamin D3 on 3'methyl-4-dimethyl-amino-azobenzene-induced rat hepatocarcinogenesis: a study on Antioxidant Defense Enzymes

Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction

Alteration of the fragile histidine triad gene early in carcinogenesis: an update

Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells

A New Beginning

Correlation of Nucleoside and Nucleobase Transporter Gene Expression with Antimetabolite Drug Cytotoxicity

Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts

Lack of toxicity of EGFR antisense gene therapy

Lymphocyte activation by granulocyte macrophage-colony stimulating factor in human bladder cancer

In vivo advantage of combined administration with CPT-11 and 5-fluorouracil in rats

Src protein kinase pp60c-src influences adhesion stabilization of HT-29 colon carcinoma cells to extracellular matrix components under dynamic conditions of laminar flow

SHOW MORE ARTICLES

Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels

A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model

Effect of thalidomide in different tumors in rodents

Effects of hexadecylphosphocholine on phosphatidylcholine and phosphatidylserine metabolism in human lymphoma cells

Chronomics*+: circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutriceuticals and beyond

Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma

Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein

Effects of etherlipid analogs on cell membrane functions

Discovery and development of anticancer agents from plants

Human chorionic gonadotropin (hCG), the hormone of life and death: a review

Title: Natural Compounds in Cancer Therapy Author: John Boik